Beta-blocker therapy for the Wolff-Parkinson-White syndrome

Eric N. Prystowsky, Stephen Greer, Douglas L Packer, Katherine A. Thompson, Lawrence D. German

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Two types of arrhythmias are associated with the Wolff-Parkinson-White syndrome: those in which the accessory pathway is a required part of the reentrant circuit, e.g., orthodromic atrioventricular reciprocating tachycardia, and those that conduct over the accessory pathway but do not require its activation for maintenance of tachycardia, e.g., atrial flutter/fibrillation. Increased sympathetic tone shortens the refractoriness of atrial and ventricular tissue; however, conduction in the atrium and ventricle is not considered the limiting factor for maintenance of atrioventricular reciprocating tachycardia or conduction over the accessory pathway in atrial arrhythmias. Intravenous β-adrenergic blockers given to patients in the resting state have a minimal to moderate effect in depressing atrioventricular nodal conduction, but have little or no effect on accessory pathway refractoriness or conduction in most patients. In patients presenting with atrioventricular reentry, intravenous administration of β-adrenergic blocking drugs often is not effective to terminate tachycardia. However, long-term oral therapy with these agents may be beneficial, especially in patients in whom enhanced sympathetic tone is responsible for the initiation or maintenance of tachycardia.

Original languageEnglish (US)
Pages (from-to)46-50
Number of pages5
JournalThe American Journal of Cardiology
Volume60
Issue number6
DOIs
StatePublished - Aug 31 1987
Externally publishedYes

Fingerprint

Wolff-Parkinson-White Syndrome
Reciprocating Tachycardia
Tachycardia
Maintenance
Cardiac Arrhythmias
Atrial Flutter
Adrenergic Antagonists
Therapeutics
Intravenous Administration
Adrenergic Agents
Atrial Fibrillation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Beta-blocker therapy for the Wolff-Parkinson-White syndrome. / Prystowsky, Eric N.; Greer, Stephen; Packer, Douglas L; Thompson, Katherine A.; German, Lawrence D.

In: The American Journal of Cardiology, Vol. 60, No. 6, 31.08.1987, p. 46-50.

Research output: Contribution to journalArticle

Prystowsky, Eric N. ; Greer, Stephen ; Packer, Douglas L ; Thompson, Katherine A. ; German, Lawrence D. / Beta-blocker therapy for the Wolff-Parkinson-White syndrome. In: The American Journal of Cardiology. 1987 ; Vol. 60, No. 6. pp. 46-50.
@article{51a8fe639a9a4d4d86d8d7d9615cbf6a,
title = "Beta-blocker therapy for the Wolff-Parkinson-White syndrome",
abstract = "Two types of arrhythmias are associated with the Wolff-Parkinson-White syndrome: those in which the accessory pathway is a required part of the reentrant circuit, e.g., orthodromic atrioventricular reciprocating tachycardia, and those that conduct over the accessory pathway but do not require its activation for maintenance of tachycardia, e.g., atrial flutter/fibrillation. Increased sympathetic tone shortens the refractoriness of atrial and ventricular tissue; however, conduction in the atrium and ventricle is not considered the limiting factor for maintenance of atrioventricular reciprocating tachycardia or conduction over the accessory pathway in atrial arrhythmias. Intravenous β-adrenergic blockers given to patients in the resting state have a minimal to moderate effect in depressing atrioventricular nodal conduction, but have little or no effect on accessory pathway refractoriness or conduction in most patients. In patients presenting with atrioventricular reentry, intravenous administration of β-adrenergic blocking drugs often is not effective to terminate tachycardia. However, long-term oral therapy with these agents may be beneficial, especially in patients in whom enhanced sympathetic tone is responsible for the initiation or maintenance of tachycardia.",
author = "Prystowsky, {Eric N.} and Stephen Greer and Packer, {Douglas L} and Thompson, {Katherine A.} and German, {Lawrence D.}",
year = "1987",
month = "8",
day = "31",
doi = "10.1016/0002-9149(87)90708-9",
language = "English (US)",
volume = "60",
pages = "46--50",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Beta-blocker therapy for the Wolff-Parkinson-White syndrome

AU - Prystowsky, Eric N.

AU - Greer, Stephen

AU - Packer, Douglas L

AU - Thompson, Katherine A.

AU - German, Lawrence D.

PY - 1987/8/31

Y1 - 1987/8/31

N2 - Two types of arrhythmias are associated with the Wolff-Parkinson-White syndrome: those in which the accessory pathway is a required part of the reentrant circuit, e.g., orthodromic atrioventricular reciprocating tachycardia, and those that conduct over the accessory pathway but do not require its activation for maintenance of tachycardia, e.g., atrial flutter/fibrillation. Increased sympathetic tone shortens the refractoriness of atrial and ventricular tissue; however, conduction in the atrium and ventricle is not considered the limiting factor for maintenance of atrioventricular reciprocating tachycardia or conduction over the accessory pathway in atrial arrhythmias. Intravenous β-adrenergic blockers given to patients in the resting state have a minimal to moderate effect in depressing atrioventricular nodal conduction, but have little or no effect on accessory pathway refractoriness or conduction in most patients. In patients presenting with atrioventricular reentry, intravenous administration of β-adrenergic blocking drugs often is not effective to terminate tachycardia. However, long-term oral therapy with these agents may be beneficial, especially in patients in whom enhanced sympathetic tone is responsible for the initiation or maintenance of tachycardia.

AB - Two types of arrhythmias are associated with the Wolff-Parkinson-White syndrome: those in which the accessory pathway is a required part of the reentrant circuit, e.g., orthodromic atrioventricular reciprocating tachycardia, and those that conduct over the accessory pathway but do not require its activation for maintenance of tachycardia, e.g., atrial flutter/fibrillation. Increased sympathetic tone shortens the refractoriness of atrial and ventricular tissue; however, conduction in the atrium and ventricle is not considered the limiting factor for maintenance of atrioventricular reciprocating tachycardia or conduction over the accessory pathway in atrial arrhythmias. Intravenous β-adrenergic blockers given to patients in the resting state have a minimal to moderate effect in depressing atrioventricular nodal conduction, but have little or no effect on accessory pathway refractoriness or conduction in most patients. In patients presenting with atrioventricular reentry, intravenous administration of β-adrenergic blocking drugs often is not effective to terminate tachycardia. However, long-term oral therapy with these agents may be beneficial, especially in patients in whom enhanced sympathetic tone is responsible for the initiation or maintenance of tachycardia.

UR - http://www.scopus.com/inward/record.url?scp=0023181665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023181665&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(87)90708-9

DO - 10.1016/0002-9149(87)90708-9

M3 - Article

C2 - 2888300

AN - SCOPUS:0023181665

VL - 60

SP - 46

EP - 50

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 6

ER -